2-Aminoindane (2-AI) is a research chemical with applications in neurologic disorders and psychotherapy that has also been sold as a designer drug.[1] It acts as a selective substrate for NET and DAT.[2][3]

Clinical data
Other names2-indanylamine;
Routes of
ATC code
  • none
Legal status
Legal status
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.019.111
Chemical and physical data
Molar mass133.190 g/mol g·mol−1
3D model (JSmol)
 NY (what is this?)  (verify)

Therapeutic and illicit uses

Synthetic aminoindanes were originally developed in the context of anti-Parkinsonian drugs as a metabolite of rasagiline and as a tool to be used in psychotherapy. Deaths related to their toxic effects have been observed both in the laboratory in animal studies and in clinical encounters.[4] 2-AI is a rigid analogue of amphetamine and partially substitutes for it in rat discrimination tests.[5]

Sweden's public health agency suggested classifying 2-AI as a hazardous substance, on June 24, 2019.[6]

Chemical derivatives

There are a number of derivatives of 2-aminoindane and its positional isomer 1-aminoindane exist, including:



As of October 2015 2-AI is a controlled substance in China.[7]

United States

2-Aminoindane is not scheduled at the federal level in the United States,[8] but may be considered an analog of amphetamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.

See also


  1. Manier, Sascha K.; Felske, Christina; Eckstein, Niels; Meyer, Markus R. (October 2019). "The metabolic fate of two new psychoactive substances − 2-aminoindane and N-methyl-2-aminoindane − studied in vitro and in vivo to support drug testing". Drug Testing and Analysis. doi:10.1002/dta.2699. ISSN 1942-7611. PMID 31667988.
  2. Halberstadt, Adam L.; Brandt, Simon D.; Walther, Donna; Baumann, Michael H. (March 2019). "2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors". 236 (3): 989–999. doi:10.1007/s00213-019-05207-1. ISSN 1432-2072. PMID 30904940. Cite journal requires |journal= (help)
  3. Simmler, Linda D.; Rickli, Anna; Schramm, York; Hoener, Marius C.; Liechti, Matthias E. (15 March 2014). "Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives". Biochemical Pharmacology. 88 (2): 237–244. doi:10.1016/j.bcp.2014.01.024. ISSN 0006-2952. PMID 24486525.
  4. Pinterova, N; Horsley, RR; Palenicek, T (2017). "Synthetic Aminoindanes: A Summary of Existing Knowledge". Frontiers in Psychiatry. 8: 236. doi:10.3389/fpsyt.2017.00236. PMC 5698283. PMID 29204127.
  5. Oberlender R, Nichols DE. (1991). "Structural variation and (+)-amphetamine-like discriminative stimulus properties". Pharmacol Biochem Behav. 38 (3): 581–586. doi:10.1016/0091-3057(91)90017-V. PMID 2068194.
  6. "Åtta ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 24 June 2019.
  7. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.